| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Over the last 12 months, insiders at vTv Therapeutics Inc. have bought $0 and sold $0 worth of vTv Therapeutics Inc. stock.
On average, over the past 5 years, insiders at vTv Therapeutics Inc. have bought $67,277 and sold $100,050 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,844 shares for transaction amount of $31,269 was made by SEKHRI PAUL J (Pres, CEO and Exec Chairperson) on 2024‑11‑18.
| 2024-11-18 | SEKHRI PAUL J | Pres, CEO and Exec Chairperson | 1,844 0.058% | $16.96 | $31,269 | +0.77% | ||
| 2024-11-15 | SEKHRI PAUL J | Pres, CEO and Exec Chairperson | 3,156 0.1377% | $16.65 | $52,543 | -2.24% | ||
| 2022-11-29 | FRY JOHN A | director | 40,461 0.0852% | $0.83 | $33,773 | -12.01% | ||
| 2022-11-28 | FRY JOHN A | director | 20,539 0.0431% | $0.83 | $16,969 | -11.38% | ||
| 2021-12-20 | Sale | PERELMAN RONALD O | director | 87,000 0.154% | $1.15 | $100,050 | -26.54% | |
| 2021-02-26 | Nelson Rich S. | director | 60,000 0.1142% | $2.86 | $171,600 | -31.58% | ||
| 2021-02-26 | KOZLOV HERSH | director | 10,000 0.0182% | $2.74 | $27,400 | -31.58% | ||
| 2020-12-17 | PERELMAN RONALD O | director | 625,000 0.9225% | $1.60 | $1M | -2.36% | ||
| 2020-12-10 | PERELMAN RONALD O | director | 625,000 0.893% | $1.60 | $1M | -4.79% | ||
| 2020-11-24 | PERELMAN RONALD O | director | 625,000 1.0514% | $1.60 | $1M | +13.44% | ||
| 2020-05-15 | KOZLOV HERSH | director | 10,000 0.022% | $3.00 | $30,000 | -22.48% | ||
| 2020-05-12 | PERELMAN RONALD O | director | 625,000 0.8555% | $1.60 | $1M | -8.98% | ||
| 2020-02-25 | PERELMAN RONALD O | director | 1.25M 1.438% | $1.60 | $2M | -33.44% | ||
| 2020-01-28 | PERELMAN RONALD O | director | 1.25M 2.1109% | $1.60 | $2M | -2.29% | ||
| 2020-01-07 | PERELMAN RONALD O | director | 1.25M 2.5998% | $1.60 | $2M | +20.34% | ||
| 2019-12-18 | PERELMAN RONALD O | director | 1.37M 4.3437% | $1.46 | $2M | +40.13% | ||
| 2019-11-26 | PERELMAN RONALD O | director | 1.37M 4.4914% | $1.46 | $2M | +42.86% | ||
| 2019-11-12 | PERELMAN RONALD O | director | 1.37M 4.3437% | $1.46 | $2M | +38.16% | ||
| 2019-10-24 | PERELMAN RONALD O | director | 1.37M 4.2053% | $1.46 | $2M | +33.76% | ||
| 2019-09-26 | PERELMAN RONALD O | director | 1.37M 4.3232% | $1.46 | $2M | +45.83% |
| PERELMAN RONALD O | director | 36519212 1395.3463% | $1.31B | 61 | 1 | +17.2% |
| SAVAS PAUL G | director | 91781 3.5068% | $3.3M | 16 | 0 | +66.67% |
| FRY JOHN A | director | 61000 2.3307% | $2.2M | 2 | 0 | <0.0001% |
| Nelson Rich S. | director | 50000 1.9104% | $1.8M | 1 | 0 | <0.0001% |
| KOZLOV HERSH | director | 25000 0.9552% | $900,000.00 | 3 | 0 | <0.0001% |
| Spiegel Noel Joseph | director | 6000 0.2293% | $216,000.00 | 2 | 0 | |
| HOWARD RUDY | CFO & Secretary | 5000 0.191% | $180,000.00 | 1 | 0 | |
| SEKHRI PAUL J | Pres, CEO and Exec Chairperson | 5000 0.191% | $180,000.00 | 2 | 0 | <0.0001% |
| Cohen Steven Michael | director | 5000 0.191% | $180,000.00 | 1 | 0 |
$5,413,611 | 159 | 6.12% | $97.13M | |
$155,630,608 | 79 | -24.53% | $99.27M | |
$17,525,882 | 60 | 5.22% | $96.22M | |
$4,898,715 | 46 | 40.75% | $92.71M | |
$7,303,100 | 45 | 7.66% | $98.91M | |
vTv Therapeutics Inc. (VTVT) | $77,146,704 | 43 | 13.28% | $94.22M |
$909,129 | 37 | 42.19% | $83.32M | |
$33,128,160 | 18 | -13.64% | $82.7M | |
$111,692,551 | 18 | 13.51% | $96.86M | |
$20,234,041 | 17 | 2.09% | $78.12M | |
$11,267,080 | 15 | -22.36% | $78M | |
$17,741,707 | 13 | 30.23% | $92.77M | |
$1,073,250 | 10 | 19.46% | $100.81M | |
$280,338 | 8 | 34.18% | $98.85M | |
$106,599,960 | 6 | -7.63% | $79.82M | |
$68,692,148 | 6 | -39.10% | $104.07M | |
$110,013 | 5 | 6.58% | $81.91M | |
$112,382,168 | 4 | -48.89% | $103.15M | |
$19,175,155 | 2 | 40.00% | $82.59M |
| Increased Positions | 15 | +71.43% | 395,930 | +40.06% |
| Decreased Positions | 6 | -28.57% | 100,587 | -10.18% |
| New Positions | 7 | New | 262,531 | New |
| Sold Out Positions | 3 | Sold Out | 22,820 | Sold Out |
| Total Postitions | 30 | +42.86% | 1M | +29.88% |
| Samsara Biocapital, Llc | $14,829.00 | 9.36% | 374,461 | +167,677 | +81.09% | 2025-09-30 |
| Fmr Llc | $7,638.00 | 4.82% | 192,891 | +14,691 | +8.24% | 2025-09-30 |
| Siren, L.L.C. | $6,455.00 | 4.08% | 163,000 | +163,000 | New | 2025-09-30 |
| Baker Bros. Advisors Lp | $5,873.00 | 3.71% | 148,314 | +51,000 | +52.41% | 2025-09-30 |
| Vanguard Group Inc | $1,861.00 | 1.18% | 46,990 | +3,815 | +8.84% | 2025-09-30 |
| Geode Capital Management, Llc | $606.00 | 0.38% | 15,298 | +2,432 | +18.9% | 2025-09-30 |
| Northern Trust Corp | $557.00 | 0.35% | 14,072 | -1,215 | -7.95% | 2025-09-30 |
| Millennium Management Llc | $512.00 | 0.32% | 12,935 | -2,107 | -14.01% | 2025-09-30 |
| Connective Capital Management, Llc | $385.00 | 0.24% | 9,712 | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $195.00 | 0.12% | 4,935 | +108 | +2.24% | 2025-09-30 |